Sign in to view content

Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies

David M. Brown, MD

Video
Published 2021

Related

VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema
Yasha S Modi, MD
Updates from the Field
2025
Biosimilar Paradox: How Biosimilar Use Will Increase Patient and Healthcare Costs
Ravi Parikh, MD MPH
Annual Meeting Talks
2023
Race Representation in Diabetic Macular Edema Randomized Control Trials Compared to the United States Census Data
Abdul-Hadi Kaakour, MD, MS
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more